The data that have been used in almost all calculations of MIRD S value absorbed dose and
effective dose are based on stylized anatomic computational phantoms and tissue-weighting …

Purpose: 68 Ga-labelled compounds are increasingly used for somatostatin-receptor
scintigraphy because of their favourable biokinetic properties, a higher tumour-to …

Abstract 177 Lu-DOTATATE (Lutathera®) enables targeted radionuclide therapy of
neuroendocrine tumors expressing somatostatin receptor type 2. Though patient-specific …

68Ga-DOTATOC and 68Ga-DOTATATE are 2 radiolabeled somatostatin analogs for in vivo
diagnosis of neuroendocrine tumors with PET. The aim of the present work was to measure …

Objectives The aim of this work was to calculate the radiation absorbed dose to kidneys,
liver, spleen, pituitary gland, and neuroendocrine tumors (NETs) of patients treated with 177 …

Measured human dosimetry of the 68Ga-labeled synthetic somatostatin analog 68Ga-
DOTATATE has not been reported in the peer-reviewed literature. 68Ga-DOTATATE is an …

Objectives: 90Y-DOTATATE is utilized for radionuclide therapy of somatostatin receptor–
positive neuroendocrine tumors. Direct imaging of the distribution of this …

Purpose The objective of this study is to determine the range of SUV max of 68Ga-
DOTATATE in normal organs and tumoral lesions and establish uptake unrelated to NET …

Quantitative imaging and dosimetry are crucial for individualized treatment during peptide
receptor radionuclide therapy (PRRT). 177Lu-DOTATATE and 68Ga-DOTATOC/68Ga …

This prospective pilot study provides a dynamic whole body PET/MR image database,
clinical safety, biodistribution profile and dosimetry of 68 Ga-DOTATOC in healthy subjects …